Table 2.

Effective treatment and relapses in selected studies

Authors	Therapy regime	Type	Number of patients	Number of effective treatments	% of effective treatment	Number of relapses	% of relapses
Açıkgöz et al.	CsA monotherapy	fmoAA	12	5	41.67	NR	NR
		AT	4	2	50.00
		AU	9	3	33.33
Ferrando and Grimalt	CsA monotherapy	fmoAA	5	2	40.00	1	6.67
		AT	2	2	100
		AU	8	3	37.50
Jang et al.	CsA monotherapy	fmoAA	40	28	54.90	22	43.14
		AT	6
		AU	5
Constantopoulos et al.	CsA monotherapy	fmoAA	6	5	83.33	5	83.33
Gupta et al.	CsA monotherapy	fmoAA	6	6	100	6	100
Lai et al.	CsA monotherapy	fmoAA	8	13	72.22	NR	NR
		AT	4
		AU	6
Yeo et al.	CsA + GCS PO	fmoAA	44	24	54.55	8	13.33
		AT	10	4	40.00
		AU	6	3	50.00
Lee D et al.	CsA + GCS PO	fmoAA	19	15	78.95	NR	NR
		AT	7	4	57.14
		AU	8	5	62.50
Lee JR et al.	CsA + GCS PO	fmoAA	19	19	100	20	80.00
		AT	6	6	100
Kim et al.	CsA + GCS PO	fmoAA	32	28	87.50	9	19.57
		AT	11	9	81.82
		AU	3	1	33.33
Shaheedi-Dadras et al.	CsA + GCS IV	AT	6	3	50.00	0	0
		AU	12	3	25.00
Shapiro et al.	CsA + GCS PO	AT	4	2	25.00	2	25.00
		AU	4
Teshima et al.	CsA + GCS PO	AU	6	6	100	0	0
Gadzhigoroeva	CsA + GCS PO	fmoAA	22	20	90.91	NR	NR

CsA cyclosporine A, GCS systemic corticosteroid, PO per os, IV intravenous, fmoAA focal, multifocal or ophiasis-type alopecia areata, AT alopecia totalis, AU alopecia universalis, NR not reported